Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report.
about
DPP4 in DiabetesIncretin based therapies: a novel treatment approach for non-alcoholic fatty liver diseaseNon-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?Non-alcoholic fatty liver disease in 2015.Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins.Dipeptidyl peptidase-4: a key player in chronic liver disease.Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment.Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.Linagliptin: from bench to bedside.Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease.DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.Treatment options for alcoholic and non-alcoholic fatty liver disease: A review.Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats.Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models.
P2860
Q26797335-40AB6792-B596-46CD-8A57-4B2C82F4302FQ26827183-F2D58247-3A0B-4421-BA6D-A033243F79B7Q27006992-61D4B9BA-5CF6-4B54-9B2D-EDE01ED7DE34Q35715883-BF7F0E80-5D8A-4207-9137-3C87308B64BEQ35964678-E5390C09-6725-4B4D-BA44-BC70E03BDCFEQ36783164-5587D2F3-2CC9-4C6D-B658-3ABC3CCCF5ACQ37375539-3FAE3BFF-374E-494E-814D-97C46138D105Q38199526-B4C23A82-E969-47A8-80F1-116C791BB66FQ38213703-7C824932-C161-48D2-95A7-C9B4050F194CQ38236774-2A46E2F5-B871-4AA0-9982-C791AEED8147Q38527138-534839EB-7A5D-4FF6-A3EF-E1622DC3F11FQ38922177-DF307D1E-7F9B-450C-BB85-B6497A10FE3EQ42695159-743B2936-42E1-4BE3-B90F-BC29F979073BQ46475564-BF46C7DD-92BA-4413-AE32-55F1EDA49D37Q51304729-D1BD156C-47B6-4C33-9472-F829A204B9C8
P2860
Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Dipeptidyl Peptidase IV Inhibi ...... isease Patient: A Case Report.
@en
Dipeptidyl Peptidase IV Inhibi ...... isease Patient: A Case Report.
@nl
type
label
Dipeptidyl Peptidase IV Inhibi ...... isease Patient: A Case Report.
@en
Dipeptidyl Peptidase IV Inhibi ...... isease Patient: A Case Report.
@nl
prefLabel
Dipeptidyl Peptidase IV Inhibi ...... isease Patient: A Case Report.
@en
Dipeptidyl Peptidase IV Inhibi ...... isease Patient: A Case Report.
@nl
P2093
P2860
P356
P1476
Dipeptidyl Peptidase IV Inhibi ...... isease Patient: A Case Report.
@en
P2093
Eitaro Taniguchi
Michio Sata
Minoru Itou
Takumi Kawaguchi
Tetsuharu Oriishi
P2860
P304
P356
10.1159/000341510
P577
2012-05-01T00:00:00Z